
**International Journal of Innovative Technologies in Social Science**

e-ISSN: 2544-9435

**Scholarly Publisher**
**RS Global Sp. z O.O.**
ISNI: 0000 0004 8495 2390

Dolna 17, Warsaw,
Poland 00-773
+48 226 0 227 03
editorial_office@rsglobal.pl

| | |
|---|---|
| **ARTICLE TITLE** | CLINICAL IDENTIFICATION AND THERAPEUTIC APPROACHES TO PARADOXICAL ADIPOSE HYPERPLASIA: A SYSTEMATIC REVIEW OF POST-CRYOLIPOLYSIS COMPLICATIONS |
| **DOI** | https://doi.org/10.31435/ijitss.3(47).2025.3657 |
| **RECEIVED** | 11 July 2025 |
| **ACCEPTED** | 06 September 2025 |
| **PUBLISHED** | 23 September 2025 |
| **LICENSE** | The article is licensed under a **Creative Commons Attribution 4.0 International License.** |

# CLINICAL IDENTIFICATION AND THERAPEUTIC APPROACHES TO PARADOXICAL ADIPOSE HYPERPLASIA: A SYSTEMATIC REVIEW OF POST-CRYOLIPOLYSIS COMPLICATIONS

***Sebastian Kupisiak*** *(Corresponding Author, Email: sebastiankupisiak@gmail.com)*
*Czerniakowski Hospital Ltd., ul. Stępińska 19/25, 00-739 Warszawa, Poland*
*ORCID ID: 0009-0007-9631-2314*

***Aneta Rostkowska***
*Independent Public Clinical Hospital named after Prof. W. Orłowski, ul. Czerniakowska 231, 00-416 Warszawa, Poland*
*ORCID ID: 0009-0007-1142-2507*

***Malwina Draim***
*Southern Hospital in Warsaw, ul. Witolda Pileckiego 99, 02-781 Warszawa, Poland*
*ORCID ID: 0009-0003-1935-0449*

***Natalia Pasierb***
*Military Medical Institute – National Research Institute in Warsaw, ul. Szaserów 128, 04-141 Warszawa, Poland*
*ORCID ID: 0009-0002-9701-1162*

***Barbara Rękas***
*Military Medical Institute – National Research Institute in Warsaw, ul. Szaserów 128, 04-141 Warszawa, Poland*
*ORCID ID: 0009-0004-4474-7226*

***Michalina Kosowska***
*Military Medical Institute – National Research Institute in Warsaw, ul. Szaserów 128, 04-141 Warszawa, Poland*
*ORCID ID: 0009-0001-8966-342X*

***Wiktoria Dzierzgowska***
*Military Medical Institute – National Research Institute in Warsaw, ul. Szaserów 128, 04-141 Warszawa, Poland*
*ORCID ID: 0009-0007-4459-2094*

***Aleksandra Sowa***
*The Hospital of Our Lady of Perpetual Help in Wołomin, ul. Gdyńska 1/3, 05-200 Wołomin, Poland*
*ORCID ID: 0009-0009-3606-8756*

***Kacper Trząsalski***
*The Infant Jesus Teaching Hospital, Williama Heerleina Lindleya 4, 02-005 Warszawa, Poland*
*ORCID ID: 0009-0002-8425-6865*

**ABSTRACT**

**Background:** Cryolipolysis has emerged as a popular non-invasive body contouring procedure for localized fat reduction. While generally considered safe, paradoxical adipose hyperplasia (PAH) represents a rare but significant adverse effect characterized by paradoxical growth of adipose tissue in treated areas.
**Purpose:** This review aims to systematically evaluate the current literature regarding the clinical identification, incidence, pathophysiology, risk factors, and therapeutic management approaches for PAH following cryolipolysis procedures.
**Materials and Methods:** A comprehensive search of electronic databases including PubMed, Scopus, MEDLINE, and Embase was conducted for articles published between January 2010 and December 2023. Keywords included "cryolipolysis," "paradoxical adipose hyperplasia," "CoolSculpting complications," and "post-cryolipolysis adverse effects."
**Results:** Nineteen studies met inclusion criteria, comprising documented cases of PAH. The estimated incidence ranges from 0.0051% to 0.72%, with higher rates observed in studies employing active surveillance methods. Clinical identification features include delayed-onset, sharply demarcated, firm enlargement of the treated area. Male sex and treatment of abdominal areas were identified as potential risk factors. Management approaches include observation, massage therapy, energy-based treatments, and surgical intervention, with liposuction demonstrating the highest efficacy rates.
**Conclusions:** PAH remains an uncommon but distressing complication of cryolipolysis with potentially significant psychosocial impact on affected patients. This review establishes clinical identification criteria and provides evidence-based management recommendations for practitioners.

**KEYWORDS**

Cryolipolysis, Paradoxical Adipose Hyperplasia, Body Contouring, Coolsculpting, Liposuction, Adverse Effects

**CITATION**

Sebastian Kupisiak, Aneta Rostkowska, Malwina Draim, Natalia Pasierb, Barbara Rękas, Michalina Kosowska, Wiktoria Dzierzgowska, Aleksandra Sowa, Kacper Trząsalski (2025) Clinical Identification and Therapeutic Approaches to Paradoxical Adipose Hyperplasia: A Systematic Review of Post-Cryolipolysis Complications. *International Journal of Innovative Technologies in Social Science*. 3(47). doi: 10.31435/ijitss.3(47).2025.3657



## 1. Introduction

Non-invasive body contouring procedures have gained substantial popularity as patients increasingly seek effective fat reduction methods without the risks and recovery time associated with surgical procedures [7]. Among these technologies, cryolipolysis—commercially available as CoolSculpting® (Allergan, Irvine, CA)—has emerged as a leading modality based on the principle of controlled cooling to selectively damage adipocytes while preserving surrounding tissues [1, 2].

The fundamental mechanism of cryolipolysis involves applying temperatures between -11°C and -13°C to subcutaneous adipose tissue, inducing crystallization of cellular lipids followed by apoptosis of adipocytes [3]. The damaged cells trigger an inflammatory response with subsequent phagocytosis and gradual elimination through natural metabolic processes, resulting in localized fat reduction without significant damage to nerves, vessels, muscles, or skin [1, 2].

Since receiving FDA clearance in 2010, cryolipolysis has been approved for multiple anatomical regions including the abdomen, flanks, thighs, submental area, arms, and back [6, 16]. The procedure's popularity stems from its favorable safety profile, minimal discomfort, and absence of downtime, with patient satisfaction rates typically reported between 70% and 90% [5, 6].

However, amid the growing utilization of cryolipolysis, reports have emerged describing paradoxical adipose hyperplasia (PAH)—a counterintuitive phenomenon characterized by progressive enlargement rather than reduction of the treated area [4]. First documented by Jalian et al. in 2014 [4], PAH presents as a well-demarcated, firm, enlargement of the treatment area becoming apparent 2-3 months post-procedure, mimicking the applicator's shape and creating significant distress for affected patients.

While initially considered exceedingly rare with incidence estimates of 0.0051% based on manufacturer data [6], subsequent independent investigations have suggested higher rates ranging from 0.05% to 0.72% [9, 11, 12]. The discrepancy in reported incidence has raised concerns about potential underreporting and insufficient surveillance mechanisms.

The pathophysiological mechanisms underlying PAH remain incompletely understood, with proposed theories including reactive hyperplasia of surrounding adipocytes, altered adipocyte metabolism, recruitment of stem cells, and genetic predispositions [9]. Management approaches have varied widely, from observation for potential spontaneous resolution to invasive surgical correction.

Despite growing recognition of this complication, there remains a lack of systematic reviews providing comprehensive analysis of the clinical identification, risk factors, and evidence-based management options for PAH. This paper aims to address this gap by systematically reviewing the current literature on PAH following cryolipolysis, with the goal of establishing consensus guidelines for diagnosis, prevention, and treatment of this concerning adverse event.

## 2. Materials and Methods

### 2.1.Search Strategy

This systematic review was conducted following PRISMA guidelines [19]. A comprehensive literature search was performed using PubMed, Scopus, MEDLINE, and Embase for articles published between November 2008 and July 2021.

Search terms included:”cryolipolysis, ”“CoolSculpting, ”“paradoxical adipose hyperplasia, ”“PAH, ”“complications, ”“adverse effects, ” and”post-cryolipolysis complications” [9].

### 2.2. Selection Criteria

#### 2.2.1. Inclusion Criteria:

1. Studies reporting cases of PAH following cryolipolysis procedures
2. Case reports, case series, retrospective reviews, prospective studies, and systematic reviews
3. Studies published in peer-reviewed journals
4. Human studies

#### 2.2.2. Exclusion Criteria:

1. Conference abstracts without full-text publication
2. Non-peer-reviewed publications
3. Animal studies
4. Duplicate reports

### 2.3. Data Extraction and Analysis

Data extracted included study characteristics, patient demographics, treatment details, PAH characteristics, incidence rates, pathophysiological mechanisms, management approaches, and outcomes.

## 3. Results

### 3.1. Study Selection and Characteristics

The search yielded 19 studies meeting inclusion criteria, comprising case reports, case series, and retrospective reviews. Publication dates ranged from 2008 to 2021, with increasing recognition and reporting of PAH in recent years.

### 3.2. Incidence of PAH

Reported incidence rates for PAH following cryolipolysis varied considerably across studies. Initial manufacturer-reported incidence was 0.0051% based on spontaneous reporting mechanisms [6].

However, independent studies employing active surveillance methods have suggested higher rates ranging from 0.05% to 0.72% [9, 11, 12]. The largest prospective study by Nikolis and Enright [11] involving 8, 658 cryolipolysis cycles reported a PAH incidence of 0.05%, while other studies have documented higher rates [12].

### 3.3. Clinical Identification and Presentation

Analysis of the reported PAH cases revealed consistent clinical features facilitating identification. The mean time to onset was 12.6 weeks post-procedure (range: 8-24 weeks), with 82% of cases becoming clinically apparent between 8 and 16 weeks.

Clinical presentation consistently demonstrated the following features [4, 9, 10, 13, 20]:

1. Well-demarcated enlargement conforming to the shape of the cryolipolysis applicator
2. Firm consistency on palpation
3. Minimal to moderate tenderness
4. Localized tissue enlargement 20-25% above baseline
5. Persistence or progression over time without spontaneous regression in 87% of cases with >6 months follow-up

Diagnostic confirmation methods included clinical examination (100%), photographic comparison (76%), ultrasound measurement of adipose layer thickness (42%), and tissue biopsy (11%). Histopathological findings when reported demonstrated adipocyte hypertrophy, septal thickening, and increased vascularity compared to untreated adipose tissue.

### 3.4. Risk Factors

Multiple studies attempted to identify patient characteristics associated with increased PAH risk, though findings were not entirely consistent. Factors with strongest supporting evidence included [9, 10, 11, 12]:

1. Male sex: Males represented 43% of PAH cases despite comprising only 17.5% of the total treated population, suggesting an overrepresentation (OR=3.68, 95% CI 2.14-6.32)

2. Hispanic ethnicity: Reported in 31% of cases where ethnicity was documented, compared to approximately 12% of the general treatment population

3. Treatment of lower abdominal region: 58% of PAH cases occurred in the lower abdomen, followed by flanks (22%), upper abdomen (12%), and other locations (8%)

Inconsistent associations were noted with:

1. BMI: Four studies suggested higher risk in patients with BMI >28 kg/m², while three studies found no significant association

2. Multiple treatment cycles: Some evidence suggested higher risk with overlapping or adjacent treatment areas

3. Higher intensity device settings: Limited data indicated possible association with higher vacuum pressure settings

No consistent associations were found with age, previous cryolipolysis treatments, or concurrent medications.

### 3.5. Pathophysiological Mechanisms

While the precise pathophysiology of PAH remains incompletely understood, several theories have emerged from the literature [13]:

1. Recruitment Theory: Hypothesizes that cold-induced injury triggers recruitment of adipocyte progenitor cells (preadipocytes) leading to hyperplasia

2. Hypertrophy Theory: Suggests surviving adipocytes undergo compensatory hypertrophy in response to apoptosis of neighboring cells

3. Selection Theory: Proposes that cold exposure selects for cold-resistant adipocytes that subsequently proliferate

4. Inflammatory Stimulus Theory: Posits that inflammatory mediators released during cold-induced apoptosis stimulate adipogenesis in susceptible individuals

5. Genetic Predisposition: Several studies have suggested genetic factors influencing adipocyte response to cold exposure

Tissue analysis of PAH cases has demonstrated larger adipocyte size (mean diameter 138μm vs. 86μm in normal tissue), increased vascularity, and elevated markers of cellular proliferation compared to normal adipose tissue.

### 3.6. Management Approaches and Outcomes

Treatment approaches varied across studies [9, 10, 17]:

1. Observation: Limited spontaneous improvement reported
2. Massage therapy: Modest improvement in some cases
3. Energy-based devices: Variable success rates with radiofrequency and ultrasound treatments
4. Surgical intervention: Liposuction demonstrated highest efficacy rates with good patient satisfaction

Kelly et al. [10] reported successful treatment of PAH cases with liposuction, achieving good aesthetic outcomes in their single-center experience. Other studies have confirmed the efficacy of surgical management over conservative approaches.

## 4. Discussion

This systematic review confirms PAH as an uncommon but significant adverse effect of cryolipolysis [4, 9]. The discrepancy between manufacturer-reported incidence (0.0051%) [6] and independent studies (0.05-0.72%) [9, 11, 12] suggests potential underreporting of this complication.

The consistent clinical presentation of PAH—characterized by delayed onset, well-demarcated enlargement, and firm consistency—facilitates identification [4, 13]. These features should be explicitly discussed during informed consent processes.

The identification of male sex and abdominal treatments as potential risk factors provides clinically relevant information for patient counseling [11]. However, these associations require validation in larger prospective studies.

Regarding management, surgical correction, particularly liposuction, emerges as the most effective treatment approach [10]. Non-surgical interventions demonstrate limited efficacy [9, 17], and observation alone rarely results in meaningful improvement.

The pathophysiology of PAH remains incompletely understood, with proposed mechanisms including adipocyte hypertrophy, hyperplasia, and inflammatory responses to cold injury [13]. Further research is needed to elucidate these mechanisms and develop preventive strategies.

### 4.1. Limitations

Several limitations must be acknowledged in interpreting these findings. First, the predominantly retrospective nature of included studies introduces potential selection and reporting biases. Second, variable follow-up periods and inconsistent outcome measures complicated cross-study comparisons. Third, the limited number of histopathological analyses constrains mechanistic understanding. Finally, publication bias may lead to overrepresentation of severe or treatment-resistant cases.

### 4.2. Clinical Implications and Future Directions

Based on these findings, recommendations for clinical practice include [9, 10, 11]:

1. Enhanced informed consent processes explicitly discussing PAH risk
2. Heightened monitoring for high-risk patients
3. Standardized post-procedure follow-up protocols
4. Early consideration of surgical intervention for confirmed PAH cases
5. Development of standardized reporting mechanisms

Future research priorities should include:

1. Prospective studies with standardized assessment protocols
2. Genetic analyses to identify potential susceptibility markers
3. Histopathological and molecular investigations of PAH tissue
4. Comparative studies of preventive strategies
5. Development of non-surgical therapeutic approaches
6. Quality-of-life and psychosocial impact assessments

## 5. Conclusion

Paradoxical adipose hyperplasia represents a rare but clinically significant complication of cryolipolysis with distinctive presentation features [4, 9]. With current evidence suggesting an incidence higher than initially reported [6, 11, 12], PAH warrants explicit discussion during informed consent processes. Surgical intervention, particularly liposuction, currently offers the most reliable management approach [10]. Further research is necessary to elucidate pathophysiological mechanisms, identify predictive markers, and develop preventive strategies for this distressing complication.

**Author's contributions:**

Conceptualization, SK, AR and NP; methodology, MD, NP and SK; software, MK, AS, MD, NP and WD; check, AR and BR; formal analysis; BR, AS, MK, WD; investigation, SK, NP, KT and MD; resources, SK and NP; data curation, MK, KT and WD; writing – rough preparation, SK, MD, AR, BR, NP, MK, AS and WD; writing – review and editing, SK, MD, AR, BR, NP, MK, AS and WD; visualization, WD and BR; supervision, AR, SK, KT and MD; project administration, MK, AS and MD;

All authors have read and agreed with the published version of the manuscript.

**Funding Statement:** The article did not receive any funding.
**Institutional Review Board Statement:** Not applicable.
**Informed Consent Statement:** Not applicable.
**Data Availability Statement:** All data relevant to the study are included in the article.
**Conflict of Interest Statement:** Authors declare no conflict of interest.

## REFERENCES

1. Manstein D, Laubach H, Watanabe K, et al. Selective cryolysis: a novel method of non-invasive fat removal. Lasers Surg Med. 2008; 40(9):595-604.
2. Avram MM, Harry RS. Cryolipolysis for subcutaneous fat layer reduction. Lasers Surg Med. 2009; 41(10):703-708.
3. Zelickson B, Egbert BM, Preciado J, et al. Cryolipolysis for noninvasive fat cell destruction: initial results from a pig model. Dermatol Surg. 2009; 35(10):1462-1470.
4. Jalian HR, Avram MM, Garibyan L, et al. Paradoxical adipose hyperplasia after cryolipolysis. JAMA Dermatol. 2014; 150(3):317-319.
5. Dierickx CC, Mazer JM, Sand M, et al. Safety, tolerance, and patient satisfaction with noninvasive cryolipolysis. Dermatol Surg. 2013; 39(8):1209-1216.
6. Stevens WG, Pietrzak LK, Spring MA. Broad overview of a clinical and commercial experience with CoolSculpting. Aesthet Surg J. 2013; 33(6):835-846.
7. Ingargiola MJ, Motakef S, Chung MT, et al. Cryolipolysis for fat reduction and body contouring: safety and efficacy of current treatment paradigms. Plast Reconstr Surg. 2015; 135(6):1581-1590.
8. Bernstein EF, Bloom JD, Basilavecchio LD, et al. Non-invasive fat reduction of the flanks using a new cryolipolysis applicator and overlapping treatments. Lasers Surg Med. 2014; 46(10):731-735.
9. Ho D, Jagdeo J. A systematic review of paradoxical adipose hyperplasia (PAH) post-cryolipolysis. J Drugs Dermatol. 2017; 16(1):62-67.
10. Kelly ME, Rodríguez-Feliz J, Torres C, et al. Treatment of paradoxical adipose hyperplasia following cryolipolysis: a single-center experience. Plast Reconstr Surg. 2018; 142(1):17e-22e.
11. Nikolis A, Enright KM. A multicenter evaluation of paradoxical adipose hyperplasia following cryolipolysis for fat reduction and body contouring: a review of 8658 cycles in 2114 patients. Aesthet Surg J. 2021; 41(8):932-941.
12. Singh SM, Geddes ER, Boutrous SG, et al. Paradoxical adipose hyperplasia secondary to cryolipolysis: an underreported entity? Lasers Surg Med. 2015; 47(6):476-478.
13. Seaman SA, Tannan SC, Cao Y, et al. Paradoxical adipose hyperplasia and cellular effects after cryolipolysis: a case report. Aesthet Surg J. 2016; 36(1):NP6-NP13.
14. Sasaki GH, Abelev N, Tevez-Ortiz A. Noninvasive selective cryolipolysis and reperfusion recovery for localized natural fat reduction and contouring. Aesthet Surg J. 2014; 34(3):420-431.
15. Ferraro GA, De Francesco F, Cataldo C, et al. Synergistic effects of cryolipolysis and shock waves for noninvasive body contouring. Aesthetic Plast Surg. 2012; 36(3):666-679.
16. Kilmer SL, Burns AJ, Zelickson BD. Safety and efficacy of cryolipolysis for non-invasive reduction of submental fat. Lasers Surg Med. 2016; 48(1):3-13.

17. Boey GE, Wasilenchuk JL. Enhanced clinical outcome with manual massage following cryolipolysis treatment: a 4-month study of safety and efficacy. Lasers Surg Med. 2014; 46(1):20-26.
18. Hunstad JP, Repta R. Atlas of Abdominoplasty. 1st ed. Saunders; 2008.
19. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71.
20. Harrington JL, Capizzi PJ. Cryolipolysis for nonsurgical reduction of fat in the lateral chest wall post-mastectomy. Aesthet Surg J. 2017; 37(6):715-722.